Diabetes, hypertension, and outcome studies: Overview 2010

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Nilsson, Peter M ^a   Cederholm, Jan ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; TRANDOLAPRIL PLUS VERAPAMIL; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ARTICLE; CORONARY ARTERY DISEASE;

ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959811620     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s204     Document Type: Review

References (49)

1. Yach D,Hawkes C, Gould CL,Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004;291:2616-2622 (Pubitemid 38702780)
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444 (Pubitemid 23046633)
3. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419 (Pubitemid 30609443)
4. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United KingdomProspective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828 (Pubitemid 28112428)
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
6. Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular andmicrovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
8. Turnbull F, Neal B, Algert C, et al.; Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165: 1410-1419 (Pubitemid 40973424)
9. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)
10. Mancia G, De Backer G, Dominiczak A, et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-1762 (Pubitemid 47356612)
11. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
12. Buse JB, Ginsberg HN, Bakris GL, et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126 (Pubitemid 46058619)
13. Mancia G, Laurent S, Agabiti-Rosei E, et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
14. Yusuf S, Diener HC, Sacco RL, et al.; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359: 1225-1237
15. Yusuf S, Teo K, Anderson C, et al. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372: 1174-1183
16. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144: 884-893 (Pubitemid 46768128)
17. Bangalore S, Messerli FH, Wun C, et al.; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of the Treating to New Targets (TNT) trial. J Am Coll Cardiol 2009;53 (Suppl. 1):A217
18. Sleight P, Redon J, Verdecchia P, et al.; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-1369
19. Redon J, Sleight P, Mancia G, et al. Safety and efficacy of aggressive blood pressure lowering among patients with diabetes: subgroup analyses from the ONTARGET trial. J Hypertens 2009;27(Suppl. 4):S16
20. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetesmellitus. N Engl JMed 2010;362: 1575-1585
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816 (Pubitemid 37509488)
22. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304: 61-68
23. Cederholm J, Gudbjörnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM; NDR. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register. J Hypertens 2010;28:2026-2035
24. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)
25. Zoungas S, de Galan BE, Ninomiya T, et al.; ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32:2068-2074
26. HanefeldM, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year followup. Diabetologia 1996;39:1577-1583 (Pubitemid 26397370)
27. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-1769 (Pubitemid 44025030)
28. Cederholm J, Zethelius B, Nilsson PM, Eeg- Olofsson K, Eliasson B, Gudbjörnsdottir S; Swedish National Diabetes Register. Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2009;86:74-81
29. Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjörnsdóttir S, Eliasson B; Steering Committee of the Swedish National Diabetes Register. Glycemic and risk factor control in type 1 diabetes: results from 13,612 patients in a national diabetes register. Diabetes Care 2007;30:496-502 (Pubitemid 46354324)
30. CederholmJ,Nilsson PM, Eliasson B, Eeg- Olofsson K, Zethelius B, Gudbjörnsdottir S; NDRs utdatagrupp. Connections between risk factors and complications in diabetes. A report after 13 years with the National Diabetes Registry (NDR). Lakartidningen 2009;106:2684-2689 [in Swedish]
31. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342 (Pubitemid 38101606)
32. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, Demicco D, Kostis JB, et al.; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. Eur Heart J 2010;31:2897-2908
33. Franklin SS. Isolated systolic hypertension and the J-curve of cardiovascular disease risk. Artery Res 2010;4:1-6
34. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 2010;362:1628-1630
35. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
36. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
37. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653 (Pubitemid 41817713)
38. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010;33: 1640-1646
39. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
40. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52: 2288-2298
41. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patientswith diabetesmellitus: ameta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
42. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009;19:604-612
43. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;151:1-10
44. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010;268:471-482
45. Skyler JS. Glycemia and cardiovascular diseases in type 2 diabetes. J Intern Med 2010;268:468-470
46. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
47. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens 2008;26:1049-1057 (Pubitemid 351670493)
48. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAMin cardiovascular risk assessment and prevention. Hypertension 2009;54:3-10
49. Edelman D, Fredrickson SK, Melnyk SD, et al. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Ann Intern Med 2010;152:689-696